PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, today announced that Pall India Pvt. Ltd. has entered into an exclusive India distribution agreement with a leading biosupplier, Spinchrom Life Sciences, a division of Spinco Biotech Pvt. Ltd. Through the agreement, Spinchrom will become the exclusive distributor to market in India ForteBio’s BLItz system, a revolutionary platform that uniquely enables scientists to conduct label-free analyses of proteins using small sample volumes easily and cost-efficiently at their laboratory bench. ForteBio is a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products.
Historically, institutions have used label-free assays selectively and relegated them to their core laboratories due to their high complexity and expense. This practice creates bottlenecks in biotherapeutic research and development, as scientists may wait days or weeks to schedule their experiments and then hours or longer to obtain results. The BLItz system is small — taking up less surface area than a tablet personal computer — so it can fit easily in an individual scientist’s workspace. It is simple to use and requires only four microliters of sample — 15 to 20 times less volume than needed for traditional, surface plasmon resonance (SPR)-based label-free assays or microplate-based ELISA assays. The BLItz system is designed for any researcher working with proteins, particularly those who analyze column fractions, monitor protein expression, perform reagent QC, identify mechanism of action and signaling and run protein engineering studies. Additionally, the BLItz system’s Dip and Read™ assays utilize disposable, ready-to-use biosensors that uniquely provide results in seconds to minutes.
“Given the growing biosimilar and proteomic activity in India, scientists’ ability to understand protein interactions is increasingly a key success factor. The BLItz technology offers great value by means of a very cost-effective, simple and fast technology platform,” says Mr. Sachin Indane, Director – BioPharm, Pall India Pvt. Ltd. “The BLItz platform will revolutionize the use of label-free protein analysis here by making it more accessible than ever to individual bench scientists and this will help to further advance biotherapeutic development in India.”
The BLItz system utilizes the same Bio-Layer Interferometry (BLI) technology that powers ForteBio’s flagship Octet® instrumentation platform, which enables real-time kinetics, affinity and quantitation measurements in high-throughput applications, with unprecedented ease of use and cost-efficiency.
“We are excited about teaming with Pall. This partnership enables us to position the innovative BLItz label-free protein analysis technology as a complementary tool to our existing Proteomics portfolio thereby offering customers comprehensive solutions for protein characterization and interaction studies,” says Mr. C. Ravindranath, Managing Director, Spinco Group of Companies.
More information about the BLItz system can be found at www.BlitzMeNow.com.
About Pall Corporation
Pall Corporation (NYSE: PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.
About ForteBio, Inc.
ForteBio is a division of Pall Life Sciences. ForteBio provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. For more information, visit www.fortebio.com.
About Spinchrom Life Sciences
Spinchrom (www.spinchrom.com) is the Life Science equipment & consumables business unit of Spinco group, ranked as the #1 Biosupplier in India. With a network of 33 Offices and 450+ Spincoites across the country, Spinchrom helps accelerate science with innovative workflow solutions.